The Francis Crick Institute
s41467-020-15615-z.pdf (3.01 MB)

Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis.

Download (3.01 MB)
journal contribution
posted on 2020-10-21, 10:02 authored by Cristina Morales Torres, Mary Y Wu, Sebastijan Hobor, Elanor N Wainwright, Matthew J Martin, Harshil Patel, William Grey, Eva Grönroos, Steven Howell, Joana Carvalho, Ambrosius P Snijders, Michael Bustin, Dominique Bonnet, Paul D Smith, Charles Swanton, Michael Howell, Paola Scaffidi
Continuous cancer growth is driven by subsets of self-renewing malignant cells. Targeting of uncontrolled self-renewal through inhibition of stem cell-related signaling pathways has proven challenging. Here, we show that cancer cells can be selectively deprived of self-renewal ability by interfering with their epigenetic state. Re-expression of histone H1.0, a tumor-suppressive factor that inhibits cancer cell self-renewal in many cancer types, can be broadly induced by the clinically well-tolerated compound Quisinostat. Through H1.0, Quisinostat inhibits cancer cell self-renewal and halts tumor maintenance without affecting normal stem cell function. Quisinostat also hinders expansion of cells surviving targeted therapy, independently of the cancer types and the resistance mechanism, and inhibits disease relapse in mouse models of lung cancer. Our results identify H1.0 as a major mediator of Quisinostat's antitumor effect and suggest that sequential administration of targeted therapy and Quisinostat may be a broadly applicable strategy to induce a prolonged response in patients.


Crick (Grant ID: 10152, Grant title: Scaffidi FC001152) Crick (Grant ID: 10169, Grant title: Swanton FC001169) Crick (Grant ID: 10045, Grant title: Bonnet FC001045) Crick (Grant ID: 10008, Grant title: Howell FC001999) Crick (Grant ID: 10011, Grant title: Snijders FC001999)